A Real-World Study of Patient Characteristics and Clinical Outcomes in <i>EGFR</i> Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice
Osimertinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR) that is used for first-line therapy in <i>EGFR</i> mutated non-small cell lung cancer (NSCLC) based on the results of the randomized FLAURA trial (ClinicalTrials.gov number NCT02296125). We performe...
Main Authors: | Hollis Viray, Andrew J. Piper-Vallillo, Page Widick, Emmeline Academia, Meghan Shea, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/6/1079 |
Similar Items
-
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience
by: A.J. Piper-Vallillo, MD, et al.
Published: (2022-06-01) -
Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report
by: Zentaro Saito, et al.
Published: (2023-10-01) -
Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
by: Alejandro Ríos-Hoyo, et al.
Published: (2022-04-01) -
Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options
by: Georgia Gomatou, et al.
Published: (2023-01-01) -
Osimertinib‐related liver injury with successful osimertinib rechallenge: A case report
by: Yuan‐Ling Cheng, et al.
Published: (2022-08-01)